Literature DB >> 15623710

Associations with autoimmune disorders and HLA class I and II antigens in inclusion body myositis.

U A Badrising1, G M Th Schreuder, M J Giphart, K Geleijns, J J G M Verschuuren, A R Wintzen, M L C Maat-Schieman, P van Doorn, B G M van Engelen, C G Faber, J E Hoogendijk, A E de Jager, P J Koehler, M de Visser, S G van Duinen.   

Abstract

Whether autoimmune mechanisms play a role in the pathogenesis of inclusion body myositis (IBM) is unknown. Human leukocyte antigen (HLA) analysis in 52 patients, including 17 with autoimmune disorders (AIDs), showed that patients were more likely to have antigens from the autoimmune-prone HLA-B8-DR3 ancestral haplotype than healthy control subjects, irrespective of the presence of AIDs. Patients lacked the apparently protective HLA-DR53 antigen. The results provide further support for an autoimmune basis in IBM.

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15623710     DOI： 10.1212/01.wnl.0000148588.15052.4c

Source DB:  PubMed          Journal:  Neurology        ISSN： 0028-3878            Impact factor:   9.910


  16 in total

1.  A Patient with Sjogren's Syndrome and Subsequent Diagnosis of Inclusion Body Myositis and Light-Chain Amyloidosis.

Authors:  Jason Hom; Shruti Marwaha; Anna Postolova; Jessie Kittle; Rosaline Vasquez; Jean Davidson; Jennefer Kohler; Annika Dries; Liliana Fernandez-Betancourt; Marta Majcherska; Joanna Dearlove; Shyam Raghavan; Hannes Vogel; Jonathan A Bernstein; Paul Fisher; Euan Ashley; Jacinda Sampson; Matthew Wheeler
Journal:  J Gen Intern Med       Date:  2019-03-18       Impact factor: 5.128

2.  A three-way interplay of DR4, autoantibodies and synovitis in biopsy-proven idiopathic inflammatory myositis.

Authors:  Vidya S Limaye; Sue Lester; Peter Bardy; Philip Thompson; Sally Cox; Peter Blumbergs; Peter Roberts-Thomson
Journal:  Rheumatol Int       Date:  2010-12-02       Impact factor: 2.631

3.  Disease specificity of autoantibodies to cytosolic 5'-nucleotidase 1A in sporadic inclusion body myositis versus known autoimmune diseases.

Authors:  Megan K Herbert; Judith Stammen-Vogelzangs; Marcel M Verbeek; Anke Rietveld; Ingrid E Lundberg; Hector Chinoy; Janine A Lamb; Robert G Cooper; Mark Roberts; Umesh A Badrising; Jan L De Bleecker; Pedro M Machado; Michael G Hanna; Lenka Plestilova; Jiri Vencovsky; Baziel G van Engelen; Ger J M Pruijn
Journal:  Ann Rheum Dis       Date:  2015-02-24       Impact factor: 19.103

4.  Targeted sequencing and identification of genetic variants in sporadic inclusion body myositis.

Authors:  Conrad C Weihl; Robert H Baloh; Youjin Lee; Tsui-Fen Chou; Sara K Pittman; Glenn Lopate; Peggy Allred; Jennifer Jockel-Balsarotti; Alan Pestronk; Matthew B Harms
Journal:  Neuromuscul Disord       Date:  2015-01-06       Impact factor: 4.296

5.  Survival and associated comorbidities in inclusion body myositis.

Authors:  Elie Naddaf; Shahar Shelly; Jay Mandrekar; Alanna M Chamberlain; E Matthew Hoffman; Floranne C Ernste; Teerin Liewluck
Journal:  Rheumatology (Oxford)       Date:  2022-05-05       Impact factor: 7.046

Review 6.  Celiac Disease-Musculoskeletal Manifestations and Mechanisms in Children to Adults.

Authors:  Haley M Zylberberg; Benjamin Lebwohl; Peter H R Green
Journal:  Curr Osteoporos Rep       Date:  2018-12       Impact factor: 5.096

Review 7.  New Developments in the Genetics of Inclusion Body Myositis.

Authors:  Kyla A Britson; Stephanie Y Yang; Thomas E Lloyd
Journal:  Curr Rheumatol Rep       Date:  2018-04-02       Impact factor: 4.592

8.  Epidemiology and Natural History of Inclusion Body Myositis: A 40-Year Population-Based Study.

Authors:  Shahar Shelly; Michelle M Mielke; Jay Mandrekar; Margherita Milone; Floranne C Ernste; Elie Naddaf; Teerin Liewluck
Journal:  Neurology       Date:  2021-04-20       Impact factor: 11.800

Review 9.  Amyloid deposits and inflammatory infiltrates in sporadic inclusion body myositis: the inflammatory egg comes before the degenerative chicken.

Authors:  Olivier Benveniste; Werner Stenzel; David Hilton-Jones; Marco Sandri; Olivier Boyer; Baziel G M van Engelen
Journal:  Acta Neuropathol       Date:  2015-01-13       Impact factor: 17.088

10.  Effect of Alemtuzumab (CAMPATH 1-H) in patients with inclusion-body myositis.

Authors:  Marinos C Dalakas; Goran Rakocevic; Jens Schmidt; Mohammad Salajegheh; Beverly McElroy; Michael O Harris-Love; Joseph A Shrader; Ellen W Levy; James Dambrosia; Robert L Kampen; David A Bruno; Allan D Kirk
Journal:  Brain       Date:  2009-05-19       Impact factor: 13.501
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.